CD4+ bias in T cells cloned from a CML patient with active graft versus leukemia effect

被引:10
作者
Dodi, IA [1 ]
Van Rhee, F
Forde, HC
Roura-Mir, C
Jaraquemada, D
Goldman, JM
Madrigal, JA
机构
[1] UCL Royal Free & Univ Coll Med Sch, Anthony Nolan Res Inst, London NW3 2QG, England
[2] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Immunol Unit, E-08193 Barcelona, Spain
[3] Hammersmith Hosp, Imperial Coll Sch Med, Dept Haematol, London, England
关键词
bone marrow; transplantation; CML; graft versus leukemia; TCR; CD4; Class II;
D O I
10.1080/146532402760271145
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background The ability to generate a GvL response by infusion of donor leukocytes (DL) in patients following relapse after BMT is now well documented and has been demonstrated to be particularly effective in patients with CML. Methods We generated T-cell lines from a patient who was undergoing an active GvL response following withdrawal of immunosuppression for cytogenetic relapse of CML. Cryopreserved pre-transplant leukemic cells were used as stimulators, to generate T-cell lines and oligoclonal lines from the lymphocytes. In total 38 sub-lines were generated from different bulk cultures. The lines were tested for their proliferative and cytotoxic capability to patient pre-transplant leukemic cells, PHA-transformed lymphoblasts, allogeneic CML cells, and autologous and allogeneic B-LCL. Results Four of the cloned lines tested recognized the patient's pre-transplant leukemic cells. Specifically, two were both cytotoxic and proliferative in response to patient leukemic cells and two were cytotoxic only. Six clonal lines recognized PHA blasts only and were proliferative; one was specific for PHA blasts and CML cells. The sub-lines were phenotyped for cell-surface markers and all were CD4(+) CD8(-) CD 16/56(-). The proliferative response of the leukemia-specific clonal lines could be blocked with anti-MHC Class II MAbs. Discussion These data suggest that CD4(+) cells play a crucial role in mediating the GvL effect in CML patients. Our observations can be used to delineate strategies for enhancing and investigating the GvL effect in CML.
引用
收藏
页码:353 / 363
页数:11
相关论文
共 31 条
[1]
Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].
Alyea, EP ;
Soiffer, RJ ;
Canning, C ;
Neuberg, D ;
Schlossman, R ;
Pickett, C ;
Collins, H ;
Wang, YL ;
Anderson, KC ;
Ritz, J .
BLOOD, 1998, 91 (10) :3671-3680
[2]
Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies [J].
Barrett, AJ ;
Malkovska, V .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :754-761
[3]
CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells [J].
Bonnett, D ;
Warren, EH ;
Greenberg, PD ;
Dick, JE ;
Riddell, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8639-8644
[4]
Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; Studies of normal polyclonal T cells and T lymphocyte clones derived early after allogeneic bone marrow transplantation [J].
Bruserud, O ;
Pawelec, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (03) :133-140
[5]
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion [J].
Claret, EJ ;
Alyea, EP ;
Orsini, E ;
Pickett, CC ;
Collins, H ;
Wang, YL ;
Neuberg, D ;
Soiffer, RJ ;
Ritz, J .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (04) :855-866
[6]
DATTA AR, 1994, BONE MARROW TRANSPL, V14, P517
[7]
DIETRICH PY, 1992, BLOOD, V80, P2419
[8]
FABER LM, 1995, BLOOD, V86, P2821
[9]
GENERATION OF LEUKEMIA-REACTIVE CYTOTOXIC LYMPHOCYTE-T CLONES FROM THE HLA-IDENTICAL BONE-MARROW DONOR OF A PATIENT WITH LEUKEMIA [J].
FABER, LM ;
VANLUXEMBURGHEIJS, SAP ;
WILLEMZE, R ;
FALKENBURG, JHF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1283-1289
[10]
CD8-DEPLETED DONOR LYMPHOCYTE INFUSION AS TREATMENT FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GIRALT, S ;
HESTER, J ;
HUH, Y ;
HIRSCHGINSBERG, C ;
RONDON, G ;
SEONG, D ;
LEE, M ;
GAJEWSKI, J ;
VANBESIEN, K ;
KHOURI, I ;
MEHRA, R ;
PRZEPIORKA, D ;
KORBLING, M ;
TALPAZ, M ;
KANTARJIAN, H ;
FISCHER, H ;
DEISSEROTH, A ;
CHAMPLIN, R .
BLOOD, 1995, 86 (11) :4337-4343